Clinical Trials Logo
  1. Home
  2. Substance Withdrawal Syndrome
  3. NCT02801357

Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction

Opiate Dependence Clinical Trial

Official title:
A Phase 1 Study to Evaluate the Relative Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction

Clinical Trial Summary

The purpose of this study is to evaluate the relative exposures of lofexidine and its major metabolites in subjects seeking buprenorphine dose reduction.

Clinical Trial Description

This is a Phase 1, open-label, inpatient study in male and female subjects seeking at least a 4 mg reduction of their buprenorphine maintenance dose. The purpose of this study is to assess the relative exposures of lofexidine and its 3 major metabolites in subjects tapering from buprenorphine maintenance treatment. Lofexidine is an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02801357
Study type Interventional
Source US WorldMeds LLC
Contact
Status Completed
Phase Phase 1
Start date June 2016
Completion date August 2016
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Completed NCT01690546 - Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence Phase 2
Completed NCT01442493 - Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment N/A
Completed NCT01389167 - Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia Phase 3
Completed NCT01182402 - Electronic Compliance Monitoring in Opioid Substitution Treatment N/A
Completed NCT00634803 - Clinical Trial of Integrated Treatment for Pain and Opioid Dependence Phase 1/Phase 2
Completed NCT00987961 - Linking Hospitalized Injection Drug Users to Buprenorphine Phase 3
Completed NCT00757744 - Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China Phase 3
Completed NCT00566969 - Cocaine Withdrawal and Pharmacotherapy Response N/A
Completed NCT00539123 - Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia N/A
Completed NCT00577408 - Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Phase 3
Recruiting NCT00241930 - Integrating Buprenorphine Into HIV Treatment Phase 4
Completed NCT00218621 - The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1 Phase 2
Completed NCT00406484 - Brief Introductory Therapy for Opioid Dependence Phase 2
Completed NCT00580827 - Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers N/A
Completed NCT03015597 - Pilot Study of Contingency Management for Smoking Cessation N/A
Completed NCT01393392 - Developing a Smoking Cessation Intervention for Methadone Maintained Smokers Phase 1
Completed NCT01416584 - A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment N/A
Recruiting NCT00439049 - Substance Abuse Pre-Treatment Screening Study
Withdrawn NCT00398008 - HIV Risk Reduction and Drug Abuse Treatment in Iran Phase 2